Erenumab: Difference between revisions
| [unchecked revision] | [unchecked revision] |
Create Erenumab page |
MDElliottMD (talk | contribs) Category taxonomy ship: retag Migraine Medicines -> Antimigraine agents |
||
| Line 19: | Line 19: | ||
[[Category:CGRP Monoclonal Antibodies]] | [[Category:CGRP Monoclonal Antibodies]] | ||
[[Category:CGRP-targeting Migraine Medicines]] | [[Category:CGRP-targeting Migraine Medicines]] | ||
[[Category: | [[Category:Antimigraine agents]] | ||
Latest revision as of 00:36, 22 May 2026
Anti-CGRP receptor monoclonal antibody
Erenumab
Aimovig
Erenumab (brand name Aimovig) was the first CGRP-pathway monoclonal antibody approved (FDA May 2018) for migraine prevention. Uniquely among the class, it targets the CGRP receptor rather than the CGRP peptide itself.
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Anti-CGRP receptor monoclonal antibody
Common uses
Preventive treatment of migraine in adults (episodic and chronic)
Pharmacy
Starting dose
70 mg SC monthly; may increase to 140 mg monthly
Preparations
70 mg/mL or 140 mg/mL prefilled autoinjector
US FDA Max
140 mg/month
Pharmacology
Routes
Subcutaneous
Onset
Onset of preventive effect over weeks; some patients respond after first dose
Duration
Monthly dosing
Half-life
~28 days
Bioavailability
~82% SC
Pregnancy
Limited data; avoid
Legal status
Rx
Purported mechanism
Humanized IgG2 monoclonal antibody binding the CGRP receptor (not the peptide); blocks CGRP-mediated vasodilation and nociceptive signaling